TY - JOUR
AU - Scherm, Angelika
AU - Ippen, Franziska Maria
AU - Hau, Peter
AU - Baurecht, Hansjörg
AU - Wick, Wolfgang
AU - Gempt, Jens
AU - Knüttel, Helge
AU - Leitzmann, Michael F
AU - Seliger, Corinna
TI - Targeted therapies in patients with newly diagnosed glioblastoma - a systematic meta-analysis of randomized clinical trials.
JO - International journal of cancer
VL - 152
IS - 11
SN - 0020-7136
CY - Bognor Regis
PB - Wiley-Liss
M1 - DKFZ-2023-00103
SP - 2373-2382
PY - 2023
N1 - 2023 Jun 1;152(11):2373-2382
AB - Glioblastoma (GB) is the most common malignant primary brain tumor in adults. The standard of care for newly diagnosed GB involves surgical resection followed by radiochemotherapy with temozolomide, with or without tumor-treating fields. In recent years, various efforts have been made to identify suitable molecularly targeted treatment options for malignant brain tumors. This meta-analysis provides an overview of recently published randomized controlled trials (RCTs) with and without molecular stratification, analyzing targeted agents in patients with newly diagnosed GB. The Cochrane Library, MEDLINE (Ovid), ClinicalTrials.gov, WHO's International Clinical Trials Registry Platform, and Google Scholar were searched for RCTs on targeted therapies in patients with newly diagnosed glioblastoma. Hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS) were extracted and pooled in a random-effects meta-analysis. Twelve RCTs (n=3,941 patients) involving protein kinase inhibitors, proteasome and histone deacetylase inhibitors, anti-angiogenic approaches, and poly (ADP-ribose) polymerase (PARP) inhibitors were included in the meta-analysis. None of the targeted agents achieved a significant benefit with regard to OS (HR=0.98 [95
KW - glioblastoma (Other)
KW - meta-analysis (Other)
KW - newly diagnosed (Other)
KW - randomized trials (Other)
KW - targeted agents (Other)
LB - PUB:(DE-HGF)16
C6 - pmid:36647335
DO - DOI:10.1002/ijc.34433
UR - https://inrepo02.dkfz.de/record/186759
ER -